Our current campaign is to keep Levemir (detemir) insulin available until a biosimilar is accessible, and to coordinate with biosimilar manufacturers in the production of detemir.

After this goal is reached, funds will be used to protect and expand treatment options for those with type 1 diabetes.

APIC does not accept funds from pharmaceutical manufacturers or any entity which might impede our ability to speak out about the need for insulin choice.

APIC

Copyright Notice

All Rights Reserved.

All materials appearing on the Alliancetoprotectinsulinchoice.org website (“content”) are protected by copyright under US Copyright laws and are the property of Alliancetoprotectinsulinchoice.org website owners or the party credited as the provider of the content. You may not copy, reproduce, distribute, publish, display, perform, modify, create derivative works, transmit, or in any way exploit any such content, nor may you distribute any part of this content over any network, including a local area network, sell or offer it for sale, or use such content to construct any kind of database. You may not alter or remove any copyright or other notice from copies of the content on the Alliancetoprotectinsulinchoice.org website. Copying or storing any content except as provided above is expressly prohibited without prior written permission of Alliancetoprotectinsulinchoice.org or the copyright holder identified in the individual content’s copyright notice. For permission to use the content on the Alliancetoprotectinsulinchoice.org website, please contact info@alliancetoprotectinsulinchoice.org

Contact us: insulinchoice@gmail.com I Alliance to Protect Insulin Choice I 3556 S. 5600 W I Suite #1-1057

Salt Lake City, UT 84120

Alliance to Protect Insulin Choice is a registered 501(c)(3) non-profit organization | Tax ID:33-2260922